选择性胆固醇吸收抑制剂临床应用中国专家共识
被引量：1
摘要
血脂异常与心血管疾病密切相关。过去十余年中，国内外先后完成了一系列里程碑式的血脂干预研究。这些研究结果有力证实，
出处
《中国处方药》
2012年第1期53-58,共6页
Journal of China Prescription Drug
参考文献35
-
1Toth PP, Catapano A, Tomassini JEet al. Update on the efficacy and safety of combination ezetimibe plus statin therapy. Lipidology. 2010, 5:655-684.
-
2Turley SD. Dietary cholesterol and the mechanisms of cholesterol absorption. Eur Herr ,/ Suppl, 1999 (Suppl S): $29-$35.
-
3Lichtension AH. Intestinal cholesterol metabolism. Ann Med, 1990, 22: 29-52.
-
4Turley SD, Dietschy JM. The intestinal absorption of biliary and dietary cholesterol as a drug target for lowering the plasma cholesterol level. Prey Cardiol, 2003. 6:29-33.
-
5Tremblay AJ, Lamarche B, Lemelin V, et al. Atorvastatin increases intestinal expression of NPCILI in hyperlipidemic men. J Lipid Res, 2011,52:558-565.
-
6Kes~lniemi YA, Miettinen TA. Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population. Eur J Clin Invest, 1987,17:391-395.
-
7Hegele associat density Guy J, Ban M, et al. NPCIL with interindividual variation lipoprotein response to ezetimibe 1 haplotype is in plasma low- . Lipids Health Dis, 2005,4:16.
-
8Simon JS, Karnoub MC, Devlin DJ, et al. Sequence variation in NPC1L1 and association with improved LDL-cholesterot lowering in response to ezetimibe treatment. Genomics, 2005, 86:648-656.
-
9Cohen JC, Pertsemlidis A, Fahmi S, et al. Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. ProcNatlAcad SciUSA, 2006, 103:1810-1815.
-
10Chen CW, Hwang JJ, Tsai CT, et al. The g.-762T>C polymorphism of the NPC1L1 gene is common in Chinese and contributes to a higher promoter activity and higher serum cholesterol levels. Journal of Human Genetics, 2009, 54: 242-247.
同被引文献24
-
1赵水平.降脂药物临床疗效评价[J].实用药物与临床,2006,9(2):67-70. 被引量：9
-
2陆新良,钱可大.丹参抗纤维化作用机制的研究进展[J].中华内科杂志,2006,45(7):608-610. 被引量：90
-
3成龙,梁日欣,杨滨,付梅红,杨洪军,黄璐琦,杨庆,王岚.红花提取物对高脂血症大鼠降脂和抗氧化的实验研究[J].中国实验方剂学杂志,2006,12(9):25-27. 被引量：65
-
4管高峰,华先平,王琳,杜令,孔祥辉.丹红注射液对动脉粥样硬化家兔脂代谢及血管内皮功能的影响[J].临床心血管病杂志,2007,23(4):304-306. 被引量：107
-
5马冬,胡国勋.阿托伐他汀加丹红注射液对冠心病血脂异常者高敏C反应蛋白及血脂的影响[J].中西医结合心脑血管病杂志,2007,5(12):1181-1183. 被引量：6
-
6Blake GJ,Ridker PM.High sensitivity C-reactive protein for predicting cardiovascular diseases:An inflammatory hypothesis[J].Eur Heart J,2001,22(5):349-352.
-
7Corrado E,Novo S.High sensitivity of C-reactive protein in primary prevention[J].G Ital Cardiol(Rome),2007,8(6):327-334.
-
8Jadad AR,Moore A,Carroll D,et al.Assessing the quality of reports of randomized clinical trials:is blinding necessary?[J].Control Clin Trials,1996,17(1):1-12.
-
9Liu Hongying,Wang Shijun,Sun Aijun,et al.Danhong inhibitsoxidized low-density lipoprotein-induced immune maturation of dentritic cells via a peroxisome proliferator activated receptorγmediated pathway[J].J Pharmacol Sci,2012,119(1):1-9.
-
10Xianming Su,Yajun He,Wei Yang,et al.Effect of Dan Hong injection on PON1,SOD activity and MDA levels in elderly patients with coronary heart disease[J].Int J Clin Exp Med,2014,7(12):5886-5889.
二级引证文献2
-
1刘施,吴嘉瑞,张晓朦,张冰.丹红注射液辅助西医常规治疗不稳定型心绞痛的系统评价[J].药物流行病学杂志,2016,25(4):209-215. 被引量：5
-
2王阶,赵涛,熊兴江,赵超,冯博,王靖怡,刘超,陈恒文,王益民,赵步长.丹红注射液治疗冠心病的作用机制与临床疗效[J].中国实验方剂学杂志,2019,25(24):173-178. 被引量：23
-
1胡大一,郭艺芳.选择性胆固醇吸收抑制剂临床应用中国专家共识(2013版)[J].浙江医学,2013,35(14):1311-1313.
-
2选择性胆固醇吸收抑制剂临床应用（2011版）中国专家共识[J].中国全科医学（医生读者版）,2011,14(7):46-46.
-
3胡大一,郭艺芳.选择性胆固醇吸收抑制剂临床应用中国专家共识（2013版）[J].中华内科杂志,2013,52(7):617-620. 被引量：9
-
4凌寒.选择性胆固醇吸收抑制剂临床应用中国专家共识(2013版)在京发布[J].中国当代医药,2013,20(13):97-97.
-
5他汀类药物与依折麦布联用提升LDL—C达标率——中国专家修订选择性胆固醇吸收抑制剂临床应用共识[J].中华医学信息导报,2011,26(14):5-5.
-
6李帮清,胡大一,陈红.大剂量辛伐他汀在高脂血症应用的有效性与安全性观察[J].中华内科杂志,2003,42(10):719-720. 被引量：3
-
7《选择性胆固醇吸收抑制剂临床应用中国专家共识(2013版)》在北京发布[J].中国医药导刊,2013,15(3):450-450.
-
8选择性胆固醇吸收抑制剂临床应用中国专家共识（2011版）[J].中国心血管病研究,2011,9(8):561-566. 被引量：4
-
9刘征.比较不同剂量辛伐他汀治疗老年高血脂症患者的效果[J].江西医药,2013,48(8):700-702. 被引量：2
-
10关注联合用药强调合理安全——选择性胆固醇吸收抑制剂临床应用中国专家共识(2013版)正式公布[J].实用心脑肺血管病杂志,2013,21(5):81-81.
